Healthcare Reform Brings Little Short-term Benefit For China’s Pharmaceutical Companies
This article was originally published in PharmAsia News
Executive Summary
China's highly anticipated healthcare reform plan rollout (PharmAsia News, Apr. 8, 2009) has raised questions, especially about the details of essential drug pricing. The new plan modifies the previous price ceiling for retail drugs to the current government-recommended prices, providing more objectivity. For instance, the rural-to-city expense ratio now stands at 3:7, which may improve to 50:50 after the reform. However, some drug makers worry that essential drugs may be fixed at a much lower rate, eroding profits for quality products. Analysts believe the pharma industry will see little profit improvement in the next three years due to thorny drug-related issues such as essential drug catalog and dissociating hospital income and drug sales. (Click here for more - Chinese language)
You may also be interested in...
China Issues Three-year Healthcare Reform Plan To Invest RMB 850 Billion
SHANGHAI - China issued its long-awaited three-year plan for its healthcare reform, and unveiled how the country will allocate RMB 850 billion ($124 billion) in the next three years
Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus
Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.